Who are NP101 - Sumatriptan iontophoretic transdermal patch's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): naratriptan HCl, Sumatriptan Succinate Oral Tablet, sumatriptan succinate/naproxen sodium, Migranal nasal spray at 4 hour, Migranal nasal spray at 1 hour, Comparator: Rizatriptan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/np101-sumatriptan-iontophoretic-transdermal-patch.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

NP101 - Sumatriptan iontophoretic transdermal patch — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NP101 - Sumatriptan iontophoretic transdermal patch (NP101 - Sumatriptan iontophoretic transdermal patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT1B/1D receptor agonist (triptan). Area: Neurology.

phase 3 5-HT1B/1D receptor agonist (triptan) 5-HT1B receptor, 5-HT1D receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

NP101 - Sumatriptan iontophoretic transdermal patch (NP101 - Sumatriptan iontophoretic transdermal patch) — NuPathe Inc.. NP101 delivers sumatriptan through the skin via iontophoresis, a technique using electrical current to enhance transdermal penetration, allowing rapid absorption without needles or oral administration.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NP101 - Sumatriptan iontophoretic transdermal patch TARGET	NP101 - Sumatriptan iontophoretic transdermal patch	NuPathe Inc.	phase 3	5-HT1B/1D receptor agonist (triptan)	5-HT1B receptor, 5-HT1D receptor
naratriptan HCl	naratriptan HCl	Cady, Roger, M.D.	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
Sumatriptan Succinate Oral Tablet	Sumatriptan Succinate Oral Tablet	Damanhour Teaching Hospital	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
sumatriptan succinate/naproxen sodium	sumatriptan succinate/naproxen sodium	GlaxoSmithKline	marketed	5-HT1B/1D receptor agonist combined with NSAID	5-HT1B receptor, 5-HT1D receptor, COX-1, COX-2
Migranal nasal spray at 4 hour	Migranal nasal spray at 4 hour	Thomas Jefferson University	marketed	Ergot alkaloid; 5-HT1B/1D receptor agonist	5-HT1B receptor, 5-HT1D receptor
Migranal nasal spray at 1 hour	Migranal nasal spray at 1 hour	Thomas Jefferson University	marketed	Ergot alkaloid; serotonin receptor agonist	5-HT1B receptor, 5-HT1D receptor
Comparator: Rizatriptan	Comparator: Rizatriptan	Organon and Co	phase 3	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT1B/1D receptor agonist (triptan) class)

NuPathe Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NP101 - Sumatriptan iontophoretic transdermal patch — Competitive Intelligence Brief. https://druglandscape.com/ci/np101-sumatriptan-iontophoretic-transdermal-patch. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing